Novo Nordisk stock rallies after Hims withdraws low cost weight loss drug
Novo Nordisk shares rose Monday after Hims and Hers scrapped its cheap weight-loss pill. The move follows regulatory pressure and legal threats from Novo.
Insights:
Telehealth provider Hims & Hers Health, Inc. has reversed its decision to launch and stopped offering a $49 compounded semaglutide weight-loss pill following legal threats from Novo Nordisk A/S and the U.S. Food and Drug Administration (FDA). The move, announced on February 9, 2026, marks the cancellation of a product that was positioned as a low-cost alternative in the weight-loss market. In the wake of the announcement, shares of Novo Nordisk A/S , headquartered in Denmark 
DK, rose 4.5% during trading.
DK, rose 4.5% during trading.
